Medical comorbidity in bipolar disorder: Relationship between illnesses of the endocrine/metabolic system and treatment outcome

Bipolar Disorders

Volumn 12, Issue 4, 2010, Pages 404-413

  Kemp, David E ^a   Gao, Keming ^a   Chan, Philip K ^a   Ganocy, Stephen J ^a   Findling, Robert L ^a   Calabrese, Joseph R ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Endocrine; Inflammation; Insulin resistance; Lithium; Medical comorbidity; Obesity; Substance use disorders; Treatment response; Valproate

Indexed keywords

LITHIUM; VALPROIC ACID;

ADULT; ARTICLE; BIPOLAR DISORDER; BIPOLAR I DISORDER; BIPOLAR II DISORDER; BODY MASS; COMORBIDITY; DEPRESSION; ENDOCRINE DISEASE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; METABOLIC DISORDER; OBESITY; PRIORITY JOURNAL; RAPID CYCLING BIPOLAR DISORDER; SUBSTANCE ABUSE; TREATMENT OUTCOME;

ADULT; BIPOLAR DISORDER; BODY MASS INDEX; COMORBIDITY; ENDOCRINE SYSTEM DISEASES; FEMALE; HUMANS; LITHIUM COMPOUNDS; MALE; METABOLIC DISEASES; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME; VALPROIC ACID;

EID: 77954856854     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/j.1399-5618.2010.00823.x     Document Type: Article

References (55)

1. Merikangas KR, Akiskal HS, Angst J. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry 2007, 64:543-552.
2. Soreca I, Fagiolini A, Frank E, Houck PR, Thompson WK, Kupfer DJ. Relationship of general medical burden, duration of illness and age in patients with bipolar I disorder. J Psychiatr Res 2008, 42:956-961.
3. Osby U, Brandt L, Correia N. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry 2001, 58:844-850.
4. Angst F, Stassen HH, Clayton PJ. Mortality of patients with mood disorders: follow-up over 34-38 years. J Affect Disord 2002, 68:167-181.
5. Roshanaei-Moghaddam B, Katon W. Premature mortality from general medical illnesses among persons with bipolar disorder: a review. Psychiatr Serv 2009, 60:147-156.
6. Elmslie JL, Silverstone JT, Mann JI, Williams SM, Romans SE. Prevalence of overweight and obesity in bipolar patients. J Clin Psychiatry 2000, 61:179-184.
7. McElroy SL, Frye MA, Suppes T. Correlates of overweight and obesity in 644 patients with bipolar disorder. J Clin Psychiatry 2002, 63:207-213.
8. Maina G, Salvi V, Vitalucci A, D'Ambrosio V, Bogetto F. Prevalence and correlates of overweight in drug-naïve patients with bipolar disorder. J Affect Disord 2008, 110:149-155.
9. Fagiolini A, Frank E, Scott JA, Turkin S, Kupfer DJ. Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disord 2005, 7:424-430.
10. Correll CU, Frederickson AM, Kane JM, Manu P. Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics. Bipolar Disord 2008, 10:788-797.
11. Fagiolini A, Frank E, Houck PR. Prevalence of obesity and weight change during treatment in patients with bipolar I disorder. J Clin Psychiatry 2002, 63:528-533.
12. Fagiolini A, Kupfer DJ, Houck PR, Novick DM, Frank E. Obesity as a correlate of outcome in patients with bipolar I disorder. Am J Psychiatry 2003, 160:112-117.
13. Beyer J, Kuchibhatla M, Gersing K, Krishnan KR. Medical comorbidity in a bipolar outpatient clinical population. Neuropsychopharmacol 2005, 30:401-404.
14. McIntyre RS, Konarski JZ, Soczynska JK. Medical comorbidity in bipolar disorder: implications for functional outcomes and health service utilization. Psychiatr Serv 2006, 57:1140-1144.
15. Pirraglia PA, Biswas K, Kilbourne AM, Fenn H, Bauer MS. A prospective study of the impact of comorbid medical disease on bipolar disorder outcomes. J Affect Disord 2009, 115:355-359.
16. Thompson WK, Kupfer DJ, Fagiolini A, Scott JA, Frank E. Prevalence and clinical correlates of medical comorbidities in patients with bipolar I disorder: analysis of acute-phase data from a randomized controlled trial. J Clin Psychiatry 2006, 67:783-788.
17. Kemp DE, Gao K, Ganocy SJ. Medical and substance use comorbidity in bipolar disorder. J Affect Disord 2009, 116:64-69.
18. Soreca I, Frank E, Kupfer DJ. The phenomenology of bipolar disorder: what drives the high rate of medical burden and determines long-term prognosis. Depress Anxiety 2009, 26:73-82.
19. Fleet-Michaliszyn SB, Soreca I, Otto AD. A prospective observational study of obesity, body composition, and insulin resistance in 18 women with bipolar disorder and 17 matched control subjects. J Clin Psychiatry 2008, 69:1892-1900.
20. McIntyre RS, Soczynska JK, Konarski JZ. Should depressive syndromes be reclassified as "metabolic syndrome type II?". Ann Clin Psychiatry 2007, 19:257-264.
21. McIntyre RS, Rasgon NL, Kemp DE. Metabolic syndrome and major depressive disorder: co-occurrence and pathophysiologic overlap. Curr Diab Rep 2009, 9:51-59.
22. Sheehan DV, Lecrubier Y, Sheehan KH. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998, 59(Suppl. 20):22-33.
23. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders 1997, Fourth Edition, Patient Version, Washington, DC, American Psychiatric Press
24. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979, 134:382-389.
25. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978, 133:429-435.
26. Endicott J, Spitzer RL, Fleiss JL, Cohen J. The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 1976, 33:766-771.
27. Linn BS, Linn MW, Gurel L. Cumulative illness rating scale. J Am Geriatr Soc 1968, 16:622-626.
28. Conwell Y, Forbes NT, Cox C, Caine ED. Validation of a measure of physical illness burden at autopsy: the Cumulative Illness Rating Scale. J Am Geriatr Soc 1993, 41:38-41.
29. Hudon C, Fortin M, Vanasse A. Cumulative Illness Rating Scale was a reliable and valid index in a family practice context. J Clin Epidemiol 2005, 58:603-608.
30. de Groot V, Beckerman H, Lankhorst GJ, Bouter LM. How to measure comorbidity. A critical review of available methods. J Clin Epidemiol 2003, 56:221-229.
31. Hudon C, Fortin M, Soubhi H. Abbreviated guidelines for scoring the Cumulative Illness Rating Scale (CIRS) in family practice. J Clin Epidemiol 2007, 60:212e1-212e4.
32. Mistry R, Gokhman I, Bastani R. Measuring medical burden using CIRS in older veterans enrolled in UPBEAT, a psychogeriatric treatment program: A pilot study. J Gerontol A Biol Sci Med Sci 2004, 59A:1068-1075.
33. Salvi F, Miller MD, Grilli A. A manual of guidelines to score the modified cumulative illness rating scale and its validation in acute hospitalized elderly patients. J Am Geriatr Soc 2008, 56:1926-1931.
34. Ruzickova M, Slaney C, Garnham J, Alda M. Clinical features of bipolar disorder with and without comorbid diabetes mellitus. Can J Psychiatry 2003, 48:458-461.
35. Regier DA, Farmer ME, Rae DS. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990, 264:2511-2518.
36. Simon GE, Von Korff M, Saunders K. Association between obesity and psychiatric disorders in the US adult population. Arch Gen Psychiatry 2006, 63:824-830.
37. McIntyre RS, McElroy SL, Konarski JZ. Substance use disorders and overweight/obesity in bipolar I disorder: preliminary evidence for competing addictions. J Clin Psychiatry 2007, 68:1352-1357.
38. Ross S, Peselow E. The neurobiology of addictive disorders. Clin Neuropharmacol 2009, 32:269-276.
39. Iosifescu DV, Nierenberg AA, Alpert JE. The impact of medical comorbidity on acute treatment in major depressive disorder. Am J Psychiatry 2003, 160:2122-2127.
40. Calkin C, van de Velde C, Růžičkovthomampersand M. Can body mass index help predict outcome in patients with bipolar disorder? Bipolar Disord 2009, 11:650-656.
41. Insel TR. Translating scientific opportunity into public health impact: a strategic plan for research on mental illness. Arch Gen Psychiatry 2009, 66:128-133.
42. Wood J, Birmaher B, Axelson D. Replicable differences in preferred circadian phase between bipolar disorder patients and control individuals. Psychiatry Res 2009, 166:201-209.
43. Soreca I, Fagiolini A, Frank E, Goodpaster BH, Kupfer DJ. Chronotype and body composition in bipolar disorder. Chronobiol Int 2009, 26:780-788.
44. Sharafkhaneh A, Giray N, Richardson P, Young T, Hirshkowitz M. Association of psychiatric disorders and sleep apnea in a large cohort. Sleep 2005, 28:1405-1411.
45. Kawahara S, Akashiba T, Akahoshi T, Horie T. Nasal CPAP improves the quality of life and lessens the depressive symptoms in patients with obstructive sleep apnea syndrome. Intern Med 2005, 44:422-427.
46. Kapczinski F, Vieta E, Andreazza AC. Allostatic load in bipolar disorder: implications for pathophysiology and treatment. Neurosci Biobehav Rev 2008, 32:675-692.
47. Fagiolini A, Frank E, Soreca I, Houck PR, Kupfer DJ. Integrating medical and psychiatric care in patients with bipolar disorder. J Clin Psychopharmacol 2008, 28:257-258.
48. Gilbody S, Bower P, Fletcher J. Collaborative care for depression: A cumulative meta-analysis and review of longerterm outcomes. Arch Intern Med 2006, 166:2314-2321.
49. Williams JW, Gerrity M, Holsinger T. Systematic review of multifaceted interventions to improve depression care. Gen Hosp Psychiatry 2007, 29:91-116.
50. Kilbourne AM, Post EP, Nossek A, Drill L, Cooley S, Bauer MS. Improving medical and psychiatric outcomes among individuals with bipolar disorder: a randomized controlled trial. Psychiatr Serv 2008, 59:760-768.
51. Owens WA, Sevak RJ, Galici R. Deficits in dopamine clearance and locomotion in hypoinsulinemic rats unmask novel modulation of dopamine transporters by amphetamine. J Neurochem 2005, 94:1402-1410.
52. Williams JM, Owens WA, Turner GH. Hypoinsulinemia regulates amphetamine-induced reverse transport of dopamine. PLoS Biol 2007, 16:5.
53. Law CW, Soczynska JK, Woldeyohannes HO, Miranda A, Brooks JO, McIntyre RS. Relation between cigarette smoking and cognitive function in euthymic individuals with bipolar disorder. Pharmacol Biochem Behav 2009, 92:12-16.
54. Kemp DE, Ismail-Beigi F, Calabrese JR. Antidepressant response associated with pioglitazone: support for an overlapping pathophysiology between major depression and metabolic syndrome. Am J Psychiatry 2009, 166:619.
55. Capuron L, Su S, Miller AH. Depressive symptoms and metabolic syndrome: is inflammation the underlying link? Biol Psychiatry 2008, 64:896-900.